Recurrent Adrenocortical Carcinoma Terminated Phase 2 Trials for Mitotane (DB00648)

IndicationStatusPhase
DBCOND0028855 (Recurrent Adrenocortical Carcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00778817IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTreatment